SuperworthNiagen Bioscience profit margin NAGE
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 12.4%
- Operating margin, 12 months
- 8.2%
- Net margin on a year earlier
- −2.9 pts
- Peer median
- 9.6%
Over the twelve months to Jun 30, 2026, Niagen Bioscience kept 12.4% of its revenue as net profit, with an operating margin of 8.2% and a gross margin of 64.2%.
Five years earlier its net margin was −37.5%.
The median for 4 chemicals stocks of a similar size is 9.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 13.4% | 12.6% | 64.3% |
| FY2024 | 8.6% | 7.8% | 61.8% |
| FY2023 | −5.9% | −6.7% | 60.8% |
| FY2022 | −23.0% | −25.9% | 59.4% |
| FY2021 | −40.2% | −40.1% | 61.5% |
| FY2020 | −33.6% | −33.5% | 59.5% |
| FY2019 | −69.4% | −67.6% | 55.7% |
| FY2018 | n/a | n/a | 50.9% |
| FY2017 | −53.7% | −77.2% | 49.4% |
| FY2016 | −13.5% | −13.4% | 48.0% |
| FY2015 | −12.6% | −9.8% | 38.5% |
| FY2014 | −35.2% | −34.2% | 34.8% |
| FY2013 | −43.5% | −43.2% | 30.8% |
| FY2012 | n/a | n/a | 19.6% |
| FY2011 | −97.3% | −96.9% | 30.5% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 12.4% | −2.9 pts | 8.2% | |
| Q1 FY26 | 14.3% | +1.2 pts | 10.0% | |
| Q4 FY25 | 13.4% | +4.8 pts | 12.6% | |
| Q3 FY25 | 16.4% | +14.8 pts | 15.5% | |
| Q2 FY25 | 15.2% | +16.8 pts | 14.3% | |
| Q1 FY25 | 13.1% | +17.3 pts | 12.3% | |
| Q4 FY24 | 8.6% | +14.5 pts | 7.8% | |
| Q3 FY24 | 1.6% | +9.4 pts | 0.5% | |
| Q2 FY24 | −1.6% | +6.4 pts | −2.7% | |
| Q1 FY24 | −4.2% | +9.6 pts | −5.2% | |
| Q4 FY23 | −5.9% | +17.0 pts | −6.7% | |
| Q3 FY23 | −7.8% | +22.0 pts | −8.2% |
Against its peers
Companies in Chemicals nearest Niagen Bioscience's size, closest first, today.
| Company | Profit margin |
|---|---|
| NAGENiagen Bioscience | 12.4% |
| FTLFFitlife Brands | 6.2% |
| FTKFlotek Industries | 13.0% |
| BTMDbiote | 3.2% |
| CRONCronos | 39.1% |
| Peer median | 9.6% |
Where Niagen Bioscience ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Niagen Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.